| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| BENAZEPRIL (has an active metabolite)
| BENAZEPRIL | CARDIOVASCULAR | ORAL | Tmax 0.75 HOUR F 37 PERCENT PPB 96.7 PERCENT SOLUBILITY SOLUBLE IN WATER | ANGIOTENSIN-CONVERTING ENZYME | ANGIOTENSIN-CONVERTING ENZYME INHIBITOR CHEMBL1808 ANGIOTENSIN-CONVERTING ENZYME P12821 ANGIOTENSIN-CONVERTING ENZYME HOMO SAPIENS ENZYME PROTEASE METALLO MAE M2 | EMA | |||
| 2 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| BENAZEPRILAT (is an active metabolite)
| BENAZEPRILAT | CARDIOVASCULAR | - | Tmax 1.5 HOUR VD 45.5 LITER (65 KILOGRAM) PPB 95.3 PERCENT Cl 3 LITER / HOUR (EQN) HT 10.5 HOUR | ANGIOTENSIN-CONVERTING ENZYME | ANGIOTENSIN-CONVERTING ENZYME INHIBITOR CHEMBL1808 ANGIOTENSIN-CONVERTING ENZYME P12821 ANGIOTENSIN-CONVERTING ENZYME HOMO SAPIENS ENZYME PROTEASE METALLO MAE M2 | EMA | |||
